Skip to content

comparison of two antipsychotics Risperidone and olanzapine in their effectiveness and side effects in treatment of Bipolar Disorder

The efficacy and adverse drug profile of Risperidone versus Olanzapine in the treatment of patients with bipolar affective disorder on combination therapy - A prospective, naturalistic, hospital based clinical study.

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2014/07/004800
Enrollment
60
Registered
2014-07-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patients clinically diagnosed to have bipolar affective disorder

Interventions

Control Intervention1: Group A: patients are not being randomized prior to treatment but only after treatment they are being categorized into group Adepending upon assigned treatment and then followed

Sponsors

Dr Manjuprasad
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: (1) patients on above mentioned age groups and sex (2) Patients on mood stabilizer Divalproaex sodium

Exclusion criteria

Exclusion criteria: (1) Age less than 18yrs and more than 65yrs. (2) Serious medical disorders endangering life. (3) Judged clinically to be at serious suicidal risk. (4) Patients on mood stabilizer other than divalproaex sodium

Design outcomes

Primary

MeasureTime frame
improment in YMRS scale, Hamilton depression rating scale in maniac and hypomaniac patients respectively and also inproment in clinical global impression scale.Timepoint: for a period of about 8 to 12weeks,every week in first month and once in 2 weeks up to 8 weeks.

Secondary

MeasureTime frame
any adverse drug reactionTimepoint: for a period of about 8 to 12weeks,every week in first month and once in 2 weeks up to 8 weeks.

Countries

India

Contacts

Public ContactDr Manjuprasad MS

Fr Muller Medical College

drvijayalaxmimk@gmail.com9845237418

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026